Evidence map›Paper›PMID 34634438›Full record

Trial reportInternational journal of radiation oncology, biology, physics2022

The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial.

Laurie W Cuttino, Linda McCall, Charlotte Kubicky, Karla V Ballman, Huong Le-Petross, Kelly K Hunt, Bruce Haffty, Kari M Rosenkranz, Judy C Boughey

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Laurie W CuttinoSarah Cannon Cancer Institute at Henrico Doctors' Hospital, Richmond, Virginia. Electronic address: laurie.cuttino@hcahealthcare.com.
Linda McCallAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Charlotte KubickyOregon Health and Science University, Portland, Oregon.
Karla V BallmanAlliance Statistics and Data Center, Weill Medical College of Cornell University, New York, New York.
Huong Le-PetrossUT-MD Anderson Cancer Center, Houston, Texas.
Kelly K HuntUT-MD Anderson Cancer Center, Houston, Texas.
Bruce HafftyRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Kari M RosenkranzDartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Judy C BougheyMayo Clinic, Rochester, Minnesota.
The University of Texas MD Anderson Cancer Center · USCornell University · USDartmouth–Hitchcock Medical Center · USDuke University · USMayo Clinic · USOregon Health & Science University · USRutgers, The State University of New Jersey · USSarah Cannon · US

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS UG1 CA189823
6 · The paper itself

Abstract

purposeHistorically, multiple ipsilateral breast cancer (MIBC) has been a contraindication to breast-conserving therapy. We report the feasibility of radiation therapy (RT) after breast-conserving therapy in MIBC from the Alliance Z11102 trial. METHODS AND MATERIALS: Delineation of targets and organs at risk was performed according to the Radiation Therapy Oncology Group contouring consensus definitions. RT was delivered to the whole breast to 45 to 50 Gy in standard daily fractions of 1.8 to 2.0 Gy. A boost of 10 to 16 Gy in 2.0-Gy daily fractions to each tumor bed was mandatory.

resultsA total of 236 eligible patients were enrolled in the study between July 23, 2012 and August 19, 2016. Of those, 195 (83%) completed RT. No patient underwent mastectomy for failure to meet the RT dose constraints. Higher absolute boost volume was associated with increased incidence of grade 2 or higher dermatitis (odds ratio, 1.21; 95% confidence interval, 1.04-1.41; P = .014). Higher relative boost volume as a percentage of the overall breast volume was not associated with increased dermatitis. Neither absolute nor relative boost volume appeared to significantly influence overall cosmesis.

conclusionsBreast conservation followed by whole breast RT plus boost to each tumor bed was feasible in the majority of patients with MIBC. Increasing radiation boost volume was associated with increased incidence of acute dermatitis, but was not associated with worse overall cosmesis.

Indexed as

Mastectomy, SegmentalBreastBreast NeoplasmsFeasibility StudiesFemaleHumansMastectomy

Identifiers

PMID34634438
PMCPMC8928138
OpenAlexW2972325411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.